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Abstract
Objective: Pulsatile forces regulate vascular remodeling and trigger vascular diseases such as saphenous vein graft disease. The saphenous
vein is exposed to high pressure and pulsatility only after implantation. Statins have been proved to reduce the incidence of vein graft failure.
Thus, we investigated the molecular mechanisms of pulsatile stretch-induced saphenous vein smooth muscle cell (SMC) proliferation and
potential beneficial effects of statins.
Methods and results: Human saphenous vein SMCs were subjected to cyclic stretch (60 cycles/min) in Flex I plates. Cerivastatin and
simvastatin significantly prevented stretch-induced increase in SMC proliferation. Stretch induced the membrane accumulation of Rho A and
Rho kinase inhibitors (Y-27632 and hydroxyfasudil) and dominant negative Rho A mutant significantly prevented stretch-induced SMC
proliferation. In addition, stretch increased the levels of both p44/42 mitogen-activated protein (MAP) kinase and Akt phosphorylation. MAP
kinase kinase (MEK)1/2 inhibitor U0126, phosphatidylinositol (PI) 3-kinase inhibitors (wortmaninn and LY294002), and dominant negative
Akt mutant significantly prevented stretch-induced SMC proliferation. Cerivastatin significantly prevented stretch-induced membrane
accumulation of Rho A. On the other hand, stretch-induced phosphorylation of p44/42 MAP kinase and Akt was not prevented by
cerivastatin. Mevalonate restored the preventive effect of cerivasatain on stretch-induced Rho A membrane accumulation. Stretch induced
hyperphosphorylation of retinoblastoma protein (pRb), which was prevented by cerivastatin and the Rho kinase inhibitors.
Conclusion: Statins prevent stretch-induced saphenous vein SMC proliferation via inhibition of the Rho/Rho-kinase pathway. This may
explain the beneficial effects of this class of drug, especially for patients after coronary artery bypass grafting.
Keywords: Stretch; SMC proliferation; Stains
1. Introduction
Vascular remodeling is an important feature of atheroscle-
rosis, restenosis and vein graft failure. Mechanical factors such
as shear stress and pulsatile stretch importantly contribute to
these events. Up to 50% of implanted saphenous veins occlude
within 10 years after implantation [1]. Saphenous vein graft
disease is composed of three different processes: thrombosis,
intimal hyperplasia, and atherosclerosis [2]. Mechanical
factors appear closely related to graft failure due to smooth
muscle cell (SMC) proliferation, which plays an important role
in the pathogenesis of intimal hyperplasia [2]. Indeed, the
saphenous vein is exposed to both high pressure and pulsatile
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stretch after implantation in the coronary circulation, while
other factors remain unchanged.
Elevated pulsatile stretch is an atherogenic stimulus [3].
Interestingly, pulsatile stretch induces proliferation of SMCs
obtained from the saphenous vein but not in internal
mammary artery [4]. Stretch-induced SMC proliferation
involves PDGF expression [5], protein kinase C activation
[6], and superoxide production [7]. In SMCs, stretch also
induces expression and translocation of early growth
response gene-1 and c-jun [8] and fibronectin gene
expression [9]. However, the precise molecular mechanisms
of the cellular responses to pulsatile stretch remain to be
elucidated.
Rho A is a member of a family of small G proteins,
which plays a central role in the organization of the actin
cytoskeleton. Activation of Rho A and its downstream
effector, Rho kinase may also be involved in stretch-induced
SMC proliferation [10]. The Rho/Rho-kinase pathway also
contributes to growth factor-induced SMC proliferation
[11,12] and neointimal formation after balloon injury [13].
Phosphatidylinositol (PI) 3-kinase is activated by growth
factors and is involved in cell cycle progression [14]. PI 3-
kinase mediates SMC proliferation after arterial injury [15]
and is required for insulin-like growth factor 1-induced
vascular SMC proliferation [16]. The serine/threonine
kinase Akt is the downstream signaling enzyme of PI 3-
kinase; in vascular SMCs it is involved in cell survival and
replication [17,18]. Thus, the PI 3-kinase/Akt pathway may
play an important role in vascular remodeling.
Statins are widely used for the treatment of hyper-
cholesterolemia. They reduce the incidence of ischemic
stroke and myocardial infarction [19,20] as well as that of
bypass graft failure [21,22]. Some benefits of statins might
be related to direct vascular effects [23].
This study was designed to elucidate the intracellular
signaling mechanisms of stretch-induced saphenous vein
SMC proliferation as well as the beneficial effects of statins.
Specifically, we addressed (1) what signaling pathways
contribute to pulsatile stretch-induced SMC proliferation
and (2) whether statins prevent stretch-induced SMC
proliferation and if so, what signaling pathway is involved
in this context.
2. Methods
2.1. Materials
Mevalonate was obtained from Sigma (Buchs, Switzer-
land), 3H-methyl-thymidine was from Amersham (Zurich,
Switzerland), wortmannin and LY294002 were from Cal-
biochem (Lucerne, Switzerland), U0126 was from Cell
Signaling (Schwalbach/Taunus, Germany). Dominant neg-
ative Rho A mutant (T19N) and Akt1 mutant (K179M)
were obtained from Upstate Biotechnology (Lake Placid,
NY) and Superfect reagent was from Qiagen (Basel,
Switzerland). Cerivastatin was supplied by Bayer AG
(Leverkusen, Germany), Simvastatin was by MSD (Glatt-
burg, Switzerland), Y-27632 ws by Welfide Corp. (Osaka,
Japan) and Hydroxyfasudil was by Asahi Chemical Industry
Co. Ltd. (Shizuoka, Japan).
Rabbit polyclonal anti-human Rho A and p27 (C19)
antibodies were obtained from Santa Cruz Biotechnology
(Basel, Switzerland), rabbit polyclonal anti-human phospho-
pRb (Ser807/811), phospho-p44/42 MAP kinase (Thr202/
Tyr204), phospho-Akt (Ser473), p44/42 MAP kinase and
Akt antibodies were from Cell Signaling, mouse mono-
clonal anti-human p21WAF1 (Ab-1) antibody was from
Calbiochem.
2.2. Cell culture
SMCs were isolated by a modified explant method from
human saphenous veins obtained from patients undergoing
coronary bypass surgery and cultured in DMEM containing
10% FCS in a humidified atmosphere (95% air/5% CO2).
Culture medium was replaced every 3 days. Experiments
were done between passages 5 and 8. The patients gave
informed consent in accordance with the Declaration of
Helsinki.
2.3. Stretch device for cultured cells
Cells were cultured onto Flex I plates coated with type-I
collagen (density, 4104/ml) with medium containing 0.2%
FCS. Flex I plates were placed on a computerized Flexercell
strain unit gasketed baseplate and were subjected to cyclic
stretch (60 cycles/min; 25% elongation at the periphery of
the culture plate bottom). Flex I culture plates not subjected
to pulsatile stretch served as controls.
2.4. Proliferation assays
To study cell growth, DNA synthesis by 3H-thymidine
(0.5 ACi/ml; 70 to 85 Ci/mol) incorporation and cell number
were measured. After each stimulation, cells were pulsed
with 3H-thymidine for 4 h and then washed with PBS before
10% trichloroacetic acid was added at 4 -C for 30 min.
Incorporated radioactivity was measured. Cell number was
determined by an electronic counter (Coulter, Instrumenten-
Gesellschaft AG, Basel, Switzerland).
2.5. MAP kinase and Akt phosphorylation
We analyzed p44/42 MAP kinase and Akt phosphor-
ylation by Western blotting using the phospho-specific
antibodies. Stimulated cells were harvested with cold
extraction buffer (120 mmol/l sodium chloride, 20 mmol/l
sodium fluoride, 1 mmol/l benzamidine, 1 mmol/l dithio-
threitol, 1 mmol/l EDTA, 6 mmol/l EGTA, 15 mmol/l
sodium pyrophosphate, 0.8 Ag/ml leupeptin, 30 mmol/l p-
nitrophenyl phosphate, 0.1 mmol/l phenylmethylsulfonyl
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fluoride and 1% NP-40, 50 mmol/l Tris, pH 8.0). Samples
were treated with 5 Laemmli SDS-PAGE sample buffer
and Western blotting with 10% SDS-PAGE gels was
performed using phospho-p44/42 MAP kinase or phos-
pho-Akt antibody.
2.6. Subcellular fractionation and Rho A membrane
accumulation
Subcellular fractionation was performed as described
[24]. Briefly, cells were harvested with hypotonic lysis
buffer (3 mmol/l MgCl2, 1 mmol/l benzamidine, 1 mmol/l
dithiothreitol, 0.8 Ag/ml leupeptin, 0.1 mmol/l phenyl-
methylsulfonyl fluoride and 20 mmol/l Tris, pH 8.0). After
three cycles of freeze and thaw, the samples were ultra-
centrifuged at 100,000g at 4 -C for 1 h. The supernatant
was saved as a cytosol fraction. The pellets were resus-
pended in lysis buffer supplemented with 1% Triton X-100
and 0.1% SDS and saved as a membrane fraction. Rho A
accumulation in each fraction was determined by Western
blotting with 15% SDS-PAGE gels using Rho A antibody.
2.6.1. Cell cycle regulatory proteins
To study the role of cell cycle regulatory proteins, cells
were harvested after 24 h stretching. Western blotting with
15% SDS-PAGE gels was performed using specific anti-
bodies against phospho-pRb, p21 and p27.
2.7. Transient transfer of dominant negative constructs
Transient transfer of dominant negative Rho A mutant
(T19N) and Akt1 mutant (K179M) were performed with
Superfect reagent [25]. Briefly, 1 Ag of dominant negative
construct was mixed with 5 Al of Superfect for 10 min in
room temperature for the complex formation. After complex
formation, the complex was given to SMCs for 3 h, and then
removed. After transfer, SMCs were cultured for 24 h to
obtain the gene expression and served for the experiments.
Transfer rate was approximately 50%.
2.8. Statistical analysis
Data are expressed as the meansTS.E.M. In all experi-
ments, n equals the number of patients from which vessels
were obtained. Multiple comparisons were made by
ANOVA followed by Fisher’s test. A p value of <0.05
was considered to be statistically significant.
3. Results
3.1. Effects of statins on stretch-induced SMC proliferation
In human saphenous vein SMCs, pulsatile stretch
significantly enhanced 3H-thymidine incorporation (Fig.
1A). Pretreatment with cerivastatin for 1 h significantly
inhibited the stretch-induced enhancement of 3H-thymidine
incorporation in a concentration-dependent manner (107–
105 mol/l, 24 h; Fig. 1A). The inhibitory effect of
cerivastatin (105 mol/l) was only partially restored by
mevalonate (Fig. 1B). Simvastatin (105 mol/l) exerted
similar inhibitory effect on stretch-induced SMC prolifer-
ation as did cerivastatin and again mevalonate only partially
restored the proliferation which was inhibited by the statin
(stretch; 178T23%, stretch plus simvastatin; 89T15%,
Fig. 1. Effects of cerivastatin on pulsatile stretch (24 h) savenous vein SMC
proliferation. (A) Pretreatment with cerivastatin prevented stretch-induced
increase in 3H-thymidine incorporation (n =3). *=p <0.01 vs. control and
stretch plus cerivastatin. (B) Inhibitory effects of cerivastatin were only
partially restored by mevalonate (n =4). *=p <0.01 vs. control and stretch
plus cerivastatin. .=p <0.05 vs. stretch plus cerivastatin. (C) Increase in
cell number to stretch was prevented by cerivastatin and cotreatment with
mevalonate only partially restored the effect of statin (n =3). *=p <0.01 vs.
control and stretch plus cerivastatin. .=p <0.05 vs. stretch plus cerivastatin.
Results are expressed as meanTS.E.M.
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stretch plus simvastatin and mevalonate; 97T12% above
control, n =3). Similarly, the increase in cell number in
response to stretch was significantly inhibited by cerivasta-
tin and this inhibitory effect of cerivastatin was only
partially restored by mevalonate (Fig. 1C). Neither cerivas-
tatin nor mevalonate had any effects on basal level of 3H-
thymidine incorporation or cell number (data not shown).
3.2. Rho/Rho-kinase pathway and SMC proliferation
Pulsatile stretch induced membrane accumulation of Rho
A as early as 20 min after stretching with maximal response
at 30 min (Fig. 2A). We tested two different Rho kinase
inhibitors, Y-27632 [26] and hydroxyfasudil [27]. In SMCs
pretreated with either one of the Rho kinase inhibitors for 1
h, stretch-induced increase in 3H-thymidine incorporation
was significantly inhibited in a concentration-dependent
manner (106–105 mol/l; Fig. 2B). Similarly, both Rho
kinase inhibitors (105 mol/l) also inhibited the increase in
cell number in response to stretch (Fig. 2C). Transient
transfer of dominant negative Rho A mutant also signifi-
cantly prevented stretch-induced increase in 3H-thymidine
incorporation (Fig. 2D). Rho kinase inhibitors did not affect
the basal level of 3H-thymidine incorporation (data not
shown).
3.3. MAP kinase pathway and SMC proliferation
Stretch induced the increase in p44/42 MAP kinase
phosphorylation level as early as 10 min after stretching with
maximal response at 30 min (Fig. 3A). The MEK1/2 inhibitor
U0126 significantly prevented the increase in 3H-thymidine
incorporation induced by pulsatile stretch (Fig. 3B).
3.4. PI 3-kinase/Akt pathway and SMC proliferation
Pulsatile stretch induced the increase in Akt phosphor-
ylation level as early as 10 min after stretching with
Fig. 2. Role of Rho/Rho-kinase pathway in stretch-induced SMC
proliferation. (A) Stretch induced membrane accumulation of Rho A with
maximal translocation at 30 min. The results of Western blot were repeated
in three independent experiments. (B) Pretreatment with Rho kinase
inhibitors prevented stretch-induced increase in 3H-thymidine incorporation
(n =3). *=p <0.01 vs. control and stretch plus Y-27632 or hydroxyfasudil.
(C) Increase in cell number to stretch was inhibited by Rho kinase inhibitors
(n =3). *=p <0.01 vs. control and stretch plus Y-27632 or hydroxyfasudil.
(D) Transient transfer of dominant negative Rho A mutant (dnRho A)
prevented stretch-induced increase in 3H-thymidine incorporation (n =3).
*=p <0.01. Results are expressed as meanTS.E.M.
Fig. 3. Role of p44/42 MAP kinase pathway in stretch-induced SMC
proliferation. (A) Stretch induced p44/42 MAP kinase phosphorylation with
maximal phosphorylation at 30 min. The results of Western blot were
repeated in three independent experiments. (B) MEK1/2 inhibitor U0126
prevented stretch-induced increase in 3H-thymidine incorporation induced
by (n =3). .=p <0.01 vs. control and stretch plus U0126. Results are
expressed as meanTS.E.M.
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maximal response at 30 min (Fig. 4A). The PI 3-kinase
inhibitors, wortmannin and LY294002 significantly pre-
vented the increase in 3H-thymidine incorporation induced
by stretch (Fig. 4B). Additionally, transient transfer of
dominant negative Akt mutant also significantly prevented
the increase in 3H-thymidine incorporation induced by
stretch (Fig. 4C).
3.5. Effects of statins on signaling pathways
To clarify the responsible signaling pathway for the
growth inhibitory effect of statins, we examined the effects
of cerivastatin and mevalonate on the signaling pathways.
Cerivastatin significantly inhibited the membrane accumu-
lation of Rho A induced by stretch (Fig. 5A). In contrast to
3H-thymidine incorporation and cell number experiments
(Fig. 1B, C), the inhibitory effect of cerivastatin on the
membrane accumulation of Rho A was fully restored by
mevalonate (Fig. 5A).
Pretreatment with cerivastatin did not affect p44/42 MAP
kinase phosphorylation, while U0126 inhibited it (Fig. 5B).
Pretreatment with cerivastatin had no effect on Akt
phosphorylation at the time point of 30 min in the cells
receiving pulsatile stretch while wortmaninn inhibited it
(Fig. 5B). However, cotreatment with mevalonate reduced
the level of Akt phosphorylation (Fig. 5B). Interestingly,
cerivastatin alone increased Akt phosphorylation level at
10 min after treatment under the condition without stretch
(Fig. 5C). In addition, mevalonate reduced the level of
Akt phosphorylation increased by cerivastatin (Fig. 5D).
To explore the interaction between the Rho/Rhokinase
pathway and the Akt pathway, we tested the effects of the
Rho kinase inhibitors on Akt phosphorylation. Both Rho
kinase inhibitors also increased Akt phosphorylation at 10
min after treatment under the condition without stretch
(Fig. 5D).
3.5.1. Cell cycle regulatory proteins and stretch
Pulsatile stretch for 24 h induced pRb hyperphosphor-
ylation and p27 downregulation whereas the expression of
p21 was not affected (Fig. 6). Cerivastatin and the Rho
kinase inhibitors, Y-27632 and hydroxyfasudil prevented
the stretch-induced pRb hyperphosphorylation but had no
effects on p27 expression (Fig. 6). Co-treatment with
mevalonate only partially reversed the inhibitory effects of
cerivastatin on pRb hyperphosphorylation (Fig. 6).
4. Discussion
Here we show that statins prevented proliferation of
human saphenous vein SMCs induced by pulsatile stretch.
Moreover, we show that stretch-induced proliferation
involved not only activation of Rho/Rho-kinase pathway
but also that of p44/42 MAP kinase and PI 3-kinase/Akt
pathways. Indeed, all three pathways were activated by
stretch and inhibition of any of these pathways completely
prevented the pulsatile stretch-induced SMC proliferation.
Thus, all three pathways are essential for saphenous vein
SMC proliferation. We also show that cerivastatin inhibited
the membrane accumulation of Rho A induced by stretch.
Statins ihhibit HMG-CoA reductase, which is a rate-limiting
enzyme of mevalonate–cholesterol pathway [28]. Activa-
tion of this pathway leads to the production of intermediates
such as all-trans geranylgeranyl pyrophosphate. This inter-
mediate is essential for Rho activation by posttranslational
modification [29]. Inhibition of this mechanism must
explain the preventive effect of cerivastatin on Rho A
activation. As the inhibition of Rho/Rho-kinase pathway is
sufficient for the inhibition of stretch-induced proliferation,
the growth inhibitory effect of statins is mediated by the
inhibition of this pathway although cerivastatin induced the
Fig. 4. Role of PI 3-kinase/Akt pathway in stretch-induced SMC
proliferation. (A) Stretch induced Akt phosphorylation with maximal
phosphorylation at 30 min. The results of Western blot were repeated in
three independent experiments. (B) PI 3-kinase inhibitors, wortmannin and
LY294002 prevented stretch-induced increase in 3H-thymidine incorpo-
ration. .=p <0.01 vs. control and stretch plus wortmannin or stretch plus
LY294002 (n =3). (C) Transient transfer of dominant negative Akt1 mutant
(dnAkt) also prevented stretch-induced increase in 3H-thymidine incorpo-
ration (n =3). .=p <0.01 vs. control and *=p =0.03 vs. stretch plus dnAkt.
Results are expressed as meanTS.E.M.
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phosphorylation of Akt, which is a positive regulator of
stretch-induced SMC proliferation.
Although cerivastatin was taken from the market because
of its muscle toxicity, both cerivastatin and simvastatin
exhibited similar inhibition of SMC proliferation, suggest-
ing a class effect must be involved. Furthermore, to confirm
whether the effects of statins are due to inhibition of the
mevalonate pathway, we examined the effect of mevalonate
on stretch-induced SMC proliferation. Indeed, mevalonate
restored the inhibitory effect of cerivastatin on Rho A
membrane translocation. However, mevalonate did not fully
restore the inhibitory effect of the statins on SMC
proliferation, confirming our previous report using PDGF
in human SMCs [23]. It is unlikely that the concentration of
Fig. 5. Effects of cerivastatin on the signaling pathways. (A) Cerivastatin prevented membrane accumulation of Rho A induced by stretch (30 min) and
cotreatment with mevalonate restored the effect of cerivastatin (n =3). * and .=p <0.05 vs. control and stretch plus cerivastatin. (B) Cerivastatin and Rho
kinase inhibitors had no significant effects on p44/42 MAP kinase and Akt phosphorylation induced by strech (30 min). Cotreatment with mevalonate reduced
phosphorylation of Akt. The results of Western blot were repeated in three independent experiments. (C) Cerivastatin alone induced phosphorylation of Akt
under the condition without stretch. The results of Western blot were repeated in three independent experiments. (D) Cotreatment with mevalonate reduced Akt
phosphorylation induced by cerivastatin (10 min). Both Rho kinase inhibitors also induced Akt phosphorylation. The results of Western blot were repeated in
three independent experiments.
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mevalonate was not high enough to restore the activity of
the mevalonate pathway since mevalonate did restore Rho A
membrane accumulation. Interestingly, however, mevalo-
nate simultaneously inhibited Akt phosphorylation, which is
essential for stretch-induced SMC proliferation. Thus,
although mevalonate fully restores one pathway (Rho A),
the simultaneous inhibition of the second pathway (Akt)
allows only partial restoration of the biological response, i.e.
proliferation induced by stretch. Since both Rho kinase
inhibitors increased the levels of Akt phosphorylation 10
min after treatment, we conclude that the Rho/Rho-kinase
pathway negatively regulates the Akt pathway in human
saphenous vein SMCs. Indeed, consistent with our results in
SMCs, Rho kinase also inversely regulates the Akt pathway
in endothelial cells [30,31]. This negative interaction
between Rho/Rho-kinase pathway and Akt may explain
the mechanism of the inhibition of Akt by mevalonate and
the activation of this pathway by cerivastatin observed in
this study.
Moreover, we investigated the effects of stretch on cell
cycle regulatory proteins. Pulsatile stretch induced pRb
phosphorylation and downregulated p27. Cerivastatin and
Rho kinase inhibitors reduced pRb phosphorylation but did
not p27 downregulation. Therefore, it is likely that hyper-
phosphorylation of pRb by stretch is mainly caused by Rho/
Rho-kinase activation.
Although arterial bypass grafting is preferable to venous
grafts because of a higher patency rate, saphenous vein
grafts are still important for emergency or multivessel
grafting. Thus, prevention of vein graft failure is still of
clinical relevance. This study demonstrated that statins
prevented savenous vein SMC proliferation via Rho/Rho-
kinase inhibition. Indeed, statins do reduce the incidence of
bypass graft failure [21,22]. Statins not only inhibit SMC
proliferation [12,23] but also augment NO release due to
phosphorylation of eNOS via activation of the Akt pathway
[32] and upregulation of eNOS expression via inhibition of
the Rho A pathway [23,33,34]. Therefore, beneficial effects
of statins on bypass graft failure must be related at the
molecular levels to both Rho/Rho-kinase inhibition and Akt
activation. Our study demonstrated that Rho kinase inhib-
itors also exhibited Akt phosphorylation. Thus, Rho kinase
inhibitors also should have beneficial effects on bypass graft
failure via inhibition of savenous vein SMC proliferation
and improvement of endothelial function.
In conclusion, Rho/Rho-kinase, p44/42 MAP kinase and
PI 3-kinase/Akt pathways are all involved in the pulsatile
stretch-induced human saphenous vein SMC proliferation
and inhibition of either of them prevents stretch-induced
SMC proliferation. Statins prevent stretch-induced saphe-
nous vein SMC proliferation via inhibition of Rho/Rho-
kinase pathway. This may explain the beneficial effects of
this class of drug, especially for patients after coronary
artery bypass grafting.
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